This prescription drug is used off-label in low doses to treat people with cancer, with notable but very preliminary successes in cases where the cancers were difficult-to-treat or quite advanced.

Safety and precautions

Naltrexone is generally safe. However, its effect on cancer is not straightforward: while many preclinical (animal or lab) studies suggest that naltrexone could help fight cancer, animals treated with naltrexone developed more aggressive cancer in at least two studies.1Kuramochi T, Sano M et al. Effects of tramadol via a µ-opioid receptor on pancreatic ductal adenocarcinoma in vitro and in vivo. Regional Anesthesia and Pain Medicine. 2024 Mar 4;49(3):200-208; Szymaszkiewicz A, Mierzejewski M et al. The role of bidirectional communication between the adipokines and the endogenous opioid system in an experimental mouse model of colitis-associated colorectal cancer. Pharmacology Reports. 2024 Feb;76(1):112-126. 

Caution is needed among people taking thyroid hormone replacement for a diagnosis of Hashimoto’s thyroiditis with low thyroid function (hypothyroidism). LDN ought to begin at the lowest range. LDN may lead to a rapid decrease in the autoimmune disorder, which then may require a rapid reduction in your dose of thyroid hormone replacement in order to avoid symptoms of hyperthyroidism; see Expert commentary in How do experts use low-dose naltrexone? ›

Side effects or adverse events

Naltrexone appears to be at least as safe as a placebo treatment. A meta-analysisa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of 89 studies found about 20 adverse events per 100 people, fewer adverse events than seen with people taking placebos.2Bolton M, Hodkinson A et al. Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis. BMC Medicine. 2019 Jan 15;17(1):10.

Typical side effects include:3Elsegood L. Ed. The LDN Book. Vermont: Chelsea Green Publishing. 2016. p. 20; Bihari B. LDN and cancer. Low Dose Naltrexone. Feb 21, 2021. Viewed September 19, 2021.

  • Difficulty sleeping, nightmares and vivid dreams
  • Transitory stomach cramps and diarrhea
  • Headache during the initial phase
  • Agitation or dizziness, or involuntary movements (infrequent)
  • Constipation and/or diarrhea: Infrequent, and more common among people with IBS, IBD, and/or Crohn’s disease
  • Elevated liver enzymes
  • Reductions in renal function (rare)

Side effects can often be prevented by starting at a low dosage and increasing by 1 mg per week until reaching 4.5 mg.4Elsegood L. Ed. The LDN Book. Vermont: Chelsea Green Publishing. 2016. p. 21.

Do not use (contraindications)

Warnings from Low Dose Naltrexone:5Bihari B. LDN and cancer. Low Dose Naltrexone. Feb 21, 2021. Viewed September 19, 2021.

Because LDN blocks opioid receptors throughout the body for three or four hours, people using opioid medication—Ultram/tramadol, morphine, dextromethorphan, Percocet/oxycodone, Duragesic/fentanyl patch, or codeine-containing medication—should not take LDN until the opioid medicine is completely out of their system. People who take daily opioid pain medication may require 10–14 days weeks of slowly weaning off opioids entirely (while first substituting full doses of non-opioid pain medications) before beginning LDN safely. But without question, use of naltrexone by anyone in this category should be discussed with their physician.

LDN users preparing for surgery generally discontinue LDN for one or two days prior to the surgery. After surgery, opioid-based medications are often used for pain management, so people should not restart LDN until cleared by their physician.

Full-dose naltrexone (50 mg) can cause liver problems among people with liver disease.

People who have received organ transplants and who therefore are taking immunosuppressivepartially or completely suppressing the immune response medication should not take LDN because it could counter the effect of those medications, which could be potentially lethal.

Keep reading about low-dose naltrexone

Authors

Sophie Kakarala

Research Assistant
View profile

Sophie received her Bachelor of Arts from the University of Cambridge, where she studied Middle Eastern languages and the philosophy of science. She then completed a premedical post-baccalaureate at the City University of New York. Before joining CancerChoices, she worked for several years at the Cornell Center for Research on End-of-Life Care, where she helped to conduct research on terminal illness and grief. Working in end-of-life research filled her with the conviction that all patients deserve free, accessible, and scientifically accurate information about the therapies available to them. While taking classes in anthropology, she also became curious about traditional medical knowledge and philosophies. These interests led her to CancerChoices. She is delighted to be part of CancerChoices’s work creating rigorous, evidence-based treatment guides for patients and physicians.

Sophie Kakarala Research Assistant

Nancy Hepp, MS

past Lead Researcher
View profile

Ms. Hepp is a researcher and communicator who has been writing and editing educational content on varied health topics for more than 20 years. She serves as lead researcher and writer for CancerChoices and also served as the first program manager. Her graduate work in research and cognitive psychology, her master’s degree in instructional design, and her certificate in web design have all guided her in writing and presenting information for a wide variety of audiences and uses. Nancy’s service as faculty development coordinator in the Department of Family Medicine at Wright State University also provided experience in medical research, plus insights into medical education and medical care from the professional’s perspective.

Nancy Hepp, MS past Lead Researcher

Reviewers

Laura Pole, MSN, RN, OCNS

Senior Clinical Consultant
View profile

Laura Pole is senior clinical consultant for CancerChoices. Laura is an oncology clinical nurse specialist who has been providing integrative oncology clinical care, navigation, consultation, and education services for over 40 years. She is the co-creator and co-coordinator of the Integrative Oncology Navigation Training at Smith Center for Healing and the Arts in Washington, DC. Laura also manages the “Media Watch Cancer News That You Can Use” listserv for Smith Center/Commonweal. In her role as a palliative care educator and consultant, Laura has served as statewide Respecting Choices Faculty for the Virginia POST (Physician Orders for Scope of Treatment) Collaborative as well as provided statewide professional education on palliative and end-of-life care for the Virginia Association for Hospices and Palliative Care.

For CancerChoices, Laura curates content and research, networks with clinical and organizational partners, brings awareness and education of integrative oncology at professional and patient conferences and programs, and translates research into information relevant to the patient experience as well as clinical practice.

Laura sees her work with CancerChoices as a perfect alignment of all her passions, knowledge and skills in integrative oncology care. She is honored to serve you.

Laura Pole, MSN, RN, OCNS Senior Clinical Consultant

Alissa Huston received her medical degree at the University of Buffalo, and went on to complete an Internal Medicine residency at Strong Memorial Hospital. She then attended the University of Pittsburgh for her Hematology/Oncology fellowship, during which time she was involved in research involving bone metastasis in cancer.

Currently, she is an Associate Professor of Medicine at the Wilmot Cancer Institute at the University of Rochester, where her clinical efforts are focused on breast cancer. She is also the Co-Medical Director of the Pluta Integrative Oncology & Wellness Center. Her research efforts focus on understanding the effects of treatment for breast cancer upon bone health and how integrative modalities can help mitigate symptoms for cancer patients as they undergo treatment.

She is a member of the American Society of Clinical Oncology and the Society for Integrative Oncology. Her philosophy is that there is no singular approach to patient care. Even though many patients may carry the same diagnosis, each individual is affected by that illness in a different way. Patients are not perceived as just a number, but instead approached and treated as the unique individuals they represent.

Alissa Huston, MD

Last update: July 27, 2025

Prior update: May 20, 2022

Full literature review dates: July 2025, September 2021

CancerChoices provides information about integrative in cancer care, a patient-centered approach combining the best of conventional care, self care and evidence-informed complementary care in an integrated plan cancer care. We review complementaryin cancer care, complementary care involves the use of therapies intended to enhance or add to standard conventional treatments; examples include supplements, mind-body approaches such as yoga or psychosocial therapy, and acupuncture therapies and self-care lifestyle actions and behaviors that may impact cancer outcomes; examples include eating health-promoting foods, limiting alcohol, increasing physical activity, and managing stress practices to help patients and professionals explore and integrate the best combination of conventionalthe cancer care offered by conventionally trained physicians and most hospitals; examples are chemotherapy, surgery, and radiotherapy and complementary therapies and practices for each person.

Our staff have no financial conflicts of interest to declare. We receive no funds from any manufacturers or retailers gaining financial profit by promoting or discouraging therapies mentioned on this site.

Learn more

References[+]